Duncan Mark W, Hunsucker Stephen W
Department of Pediatrics, Section of Pulmonary Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA.
Exp Biol Med (Maywood). 2005 Dec;230(11):808-17. doi: 10.1177/153537020523001105.
The excitement associated with clinical applications of proteomics was initially focused on its potential to serve as a vehicle for both biomarker discovery and drug discovery and routine clinical sample analysis. Some approaches were thought to be able to "identify" mass spectral characteristics that distinguished between control and disease samples, and thereafter it was believed that the same tool could be employed to screen samples in a high-throughput clinical setting. However, this has been difficult to achieve, and the early promise is yet to be fully realized. While we see an important place for mass spectrometry in drug and biomarker discovery, we believe that alternative strategies will prove more fruitful for routine analysis. Here we discuss the power and versatility of 2D gels and mass spectrometry in the discovery phase of biomarker work but argue that it is better to rely on immunochemical methods for high-throughput validation and routine assay applications.
